NewAmsterdam Pharma Co N.V.
NAMSNasdaq
$31.68
↑ +2.0%Jul 17 close · end-of-day
Price
1Y↑ +51.4%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$3.9B
Enterprise Value
$3.2B
P/E
—
P/S
170.9
P/B
5.8
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
$22.6M
Net Income (TTM)
-$211.9M
Free Cash Flow (TTM)
—
Gross Margin
—
Operating Margin
-953.6%
Net Margin
-939.1%
ROE
-31.9%
ROIC
-583.8%
Debt / Equity
—
Net Cash
$636.1M
Return 1Y
+44.1%
Company profile
- CEO
- Michael H. Davidson
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 4
- Website
- newamsterdampharma.com
Management & directors
- Kooij Louise FrederikaChief Accounting Officer
- Kastelein Johannes Jacob PieterChief Scientific Officer
- Davidson Michael H.Chief Executive Officer
- Somaiya Mayur IanChief Financial Officer
- Kling Douglas FChief Operating Officer
Roles derived from SEC Form 4 filings.
Earnings
NAMS Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$3.0M↑ +2.1%
Diluted EPS-$0.40↑ +17.6%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | — | $102.7M | $14.1M | $45.6M | $22.5M |
| Gross profit | — | — | — | — | — |
| Operating income | -$35.0M | -$3.6M | -$183.0M | -$176.3M | -$225.7M |
| Net income | -$41.8M | -$22.6M | -$177.0M | -$242.0M | -$203.0M |
| Diluted EPS | -$3.81 | -$1.19 | -$2.15 | -$2.56 | -$1.72 |
| Operating cash flow | -$29.5M | $10.7M | -$141.2M | -$158.6M | -$147.8M |
| Free cash flow | — | — | — | — | — |
| Gross margin | — | — | — | — | — |
| Operating margin | — | -3.5% | -1298.6% | -386.9% | -1002.9% |
| Net margin | — | -22.0% | -1256.2% | -531.1% | -902.1% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $2.3M | $29.1M | $12.8M | $3.0M | $19.1M | $348,000.00 | $32,000.00 | $3.0M |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$52.6M | -$25.0M | -$43.2M | -$68.9M | -$35.6M | -$55.1M | -$66.0M | -$58.4M |
| Net income | -$39.0M | -$16.6M | -$92.6M | -$39.5M | -$17.4M | -$72.0M | -$74.1M | -$48.4M |
| Diluted EPS | -$0.41 | -$0.18 | -$0.91 | -$0.34 | -$0.15 | -$0.61 | -$0.62 | -$0.40 |
| Operating cash flow | -$54.0M | -$12.5M | -$37.5M | -$36.5M | -$37.7M | -$32.8M | -$40.9M | -$30.6M |
| Free cash flow | — | — | — | — | — | — | — | — |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | -2306.9% | -85.9% | -338.5% | -2314.5% | -186.1% | -15845.7% | -206187.5% | -1921.7% |
| Net margin | -1711.6% | -57.2% | -724.9% | -1327.3% | -90.7% | -20691.1% | -231575.0% | -1593.5% |
Company news
Jul 15, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-06-22 | Kooij Louise Frederika· Chief Accounting Officer | Sale | 39,700 | $30.20 | $1.2M | filing |
| 2026-06-22 | Kooij Louise Frederika· Chief Accounting Officer | Option exercise | 25,000 | $10.90 | $272,500.00 | filing |
| 2026-06-22 | Kooij Louise Frederika· Chief Accounting Officer | Option exercise | 15,000 | $11.90 | $178,500.00 | filing |
| 2026-06-22 | Kooij Louise Frederika· Chief Accounting Officer | Sale | 300 | $30.73 | $9,219.00 | filing |
| 2026-05-26 | Kooij Louise Frederika· Chief Accounting Officer | Sale | 65,000 | $35.69 | $2.3M | filing |
| 2026-05-26 | Kooij Louise Frederika· Chief Accounting Officer | Option exercise | 60,000 | $10.00 | $600,000.00 | filing |
| 2026-05-26 | Kooij Louise Frederika· Chief Accounting Officer | Option exercise | 5,000 | $10.90 | $54,500.00 | filing |
| 2026-03-11 | LANGE LOUIS G | Sale | 44,173 | $30.41 | $1.3M | filing |
| 2026-03-11 | LANGE LOUIS G | Sale | 446 | $31.23 | $13,928.58 | filing |
| 2026-03-09 | Kastelein Johannes Jacob Pieter· Chief Scientific Officer | Sale | 101,409 | $30.29 | $3.1M | filing |
| 2026-03-09 | Kastelein Johannes Jacob Pieter· Chief Scientific Officer | Option exercise | 101,409 | — | — | filing |
| 2026-03-06 | Kastelein Johannes Jacob Pieter· Chief Scientific Officer | Sale | 94,124 | $30.32 | $2.9M | filing |
| 2026-03-06 | Kastelein Johannes Jacob Pieter· Chief Scientific Officer | Option exercise | 94,124 | — | — | filing |
| 2026-03-05 | Kastelein Johannes Jacob Pieter· Chief Scientific Officer | Sale | 104,467 | $30.30 | $3.2M | filing |
| 2026-03-05 | Kastelein Johannes Jacob Pieter· Chief Scientific Officer | Option exercise | 104,467 | — | — | filing |
| 2026-03-02 | Davidson Michael H.· Chief Executive Officer | Sale | 443,707 | $33.25 | $14.8M | filing |
| 2026-03-02 | Davidson Michael H.· Chief Executive Officer | Option exercise | 443,707 | — | — | filing |
| 2026-02-26 | Davidson Michael H.· Chief Executive Officer | Sale | 165,408 | $33.63 | $5.6M | filing |
| 2026-02-26 | Davidson Michael H.· Chief Executive Officer | Sale | 17,924 | $34.44 | $617,302.56 | filing |
| 2026-02-26 | Davidson Michael H.· Chief Executive Officer | Option exercise | 183,332 | — | — | filing |
| 2026-02-25 | Davidson Michael H.· Chief Executive Officer | Sale | 46,517 | $35.11 | $1.6M | filing |
| 2026-02-25 | Davidson Michael H.· Chief Executive Officer | Sale | 10,436 | $35.96 | $375,278.56 | filing |
| 2026-02-25 | Davidson Michael H.· Chief Executive Officer | Sale | 1,300 | $36.68 | $47,684.00 | filing |
| 2026-02-25 | Davidson Michael H.· Chief Executive Officer | Option exercise | 58,253 | — | — | filing |
| 2026-02-24 | Davidson Michael H.· Chief Executive Officer | Sale | 61,547 | $36.13 | $2.2M | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.